Advertisement


Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Welcome and Introduction to Vi3C

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Advertisement

Advertisement




Advertisement